Medical Loss Ratio rule symbolic at best, sure to drive out innovation
PPACA's provisions make grim assumptions about the market and its ability to self-correct

 

No one who understands this business believes a health insurance company should deliver only 65 or 70 cents worth of care for every dollar collected. But the architects of the Patient Protection and Affordable Care Act (PPACA) can point to moments over the past decades when the medical loss ratios (MLRs) of some profitable insurers dipped that low. The market took two enrollment periods to correct, and many of those same plans were underwater three years later.

The MLR itself naturally becomes the accounting target for everyone who believes that health insurers are denying people not just reimbursement, but treatment, life and hope. Had PPACA's 80% and 85% MLR rule been applied to 2010, insurers would have refunded approximately $2 billion collectively. The rule essentially assumes that:

Health insurance markets do not work;

Most of these "markets" are controlled by cabals of large, price-fixing insurers;

Employers are dupes who cannot price discriminate, nor negotiate, and are simply happy to pass along excessive premiums to employees;

Agents and brokers actually benefit from prices kept artificially high by this market failure; and

Health insurers can and will gouge customers and get away with it forever.

The overarching goal of PPACA is to flatten and broaden coverage, reallocating funds from the insured to the uninsured, based on the hard reality that this reallocation occurs anyway, through the grossly inefficient mechanisms of provider mark-ups and cross-subsidies. Because the MLR calculations govern the largest countable pots of money in the healthcare system, they seem like an obvious tool for re-engineering—especially given how politically easy it is to go after "excessive" insurer profits.

In reality, the $2 billion refund would amount to less than one-quarter of 1% of what all enrollees spent on health insurance in 2010. So how will the imposition of the MLR refund rule radically reshape the pricing and distribution of health insurance—soon to be a $1 trillion marketplace or 500 times the size of that 2010 refund?

The industry—which engaged in much of the PPACA debate in good faith—is understandably hyperventilating about the effects of a rule loaded with populist symbolism, if not actual financial firepower. They react to what is yet another cumbersome and barely material compliance ritual—one fraught with huge public-relations risks.

In terms of innovation for the industry, consider where almost all the venture capital in healthcare has fled: consumer health, provider IT, health 2.0, and provider consolidation, with almost nothing going toward new and better forms of health insurance. Much of this venture capital originates with the large insurers themselves, in a desperate search for revenue diversification ahead of PPACA and MLR deadlines.

Forget about the emergence of bold new players who can significantly change the health insurance game. The MLR rule is a profit-regulation mechanism, plain and simple. Like all other forms of price controls, this one will drive away innovators and capital and send all of today's players into a dogfight for total profit growth (versus profit margin growth) through consolidation.

If the federal government wants to convert health insurers into profit-regulated public utilities—with a capital base and innovation culture to match—that may be precisely what it gets.

J.D. Kleinke is a medical economist, author and MHE editorial advisor. He was appointed a resident Fellow at the American Enterprise Institute earlier this month.

 

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

J.D.
Kleinke
  • J. D. Kleinke, an expert on health care business strategy and entrepreneurship, was instrumental in the creation of four health care information organizations. He has also advised established and start-up companies on health care business, product and technology strategy. Mr. Kleinke writes on the business of health care, health insurance and benefits as well as about doctors and the culture of medicine. His books include Bleeding Edge: The Business of Health Care in the New Century (Jones & Bartlett Learning, 1998), Oxymorons: The Myth of a U.S. Health Care System (Jossey-Bass, 2001), and Catching Babies (Fourth Chapter Books, 2011). At AEI, he is studying the interplay between health policy, health care market dynamics and health venture formation; the influence of information technology and medical technology on the overall health economy; and the impact of medical culture on health care organizations, markets and public health.

  • Phone: 202 862 5846
    Email: jd.kleinke@aei.org
  • Assistant Info

    Name: Catherine Griffin
    Phone: 202 862 5920
    Email: catherine.griffin@aei.org

What's new on AEI

image The Census Bureau and Obamacare: Dumb decision? Yes. Conspiracy? No.
image A 'three-state solution' for Middle East peace
image Give the CBO long-range tools
image The coming collapse of India's communists
AEI on Facebook
Events Calendar
  • 14
    MON
  • 15
    TUE
  • 16
    WED
  • 17
    THU
  • 18
    FRI
Wednesday, April 16, 2014 | 10:00 a.m. – 11:00 a.m.
Calling treason by its name: A conversation with Liam Fox

Join us at AEI as the Right Honorable Liam Fox sits down with Marc Thiessen to discuss and debate whether America’s intelligence agencies have infringed on the personal privacy of US citizens.

Thursday, April 17, 2014 | 4:00 p.m. – 5:00 p.m.
The curmudgeon's guide to getting ahead

How can young people succeed in workplaces dominated by curmudgeons who are judging their every move? At this AEI book event, bestselling author and social scientist Charles Murray will offer indispensable advice for navigating the workplace, getting ahead, and living a fulfilling life.

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.